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Abstract: Sea anemone venoms comprise multifarious peptides modulating biological targets such
as ion channels or receptors. The sequence of a new Kunitz-type peptide, HCRG21, belonging
to the Heteractis crispa RG (HCRG) peptide subfamily was deduced on the basis of the gene
sequence obtained from the Heteractis crispa cDNA. HCRG21 shares high structural homology
with Kunitz-type peptides APHC1–APHC3 from H. crispa, and clusters with the peptides from
so named “analgesic cluster” of the HCGS peptide subfamily but forms a separate branch on the
NJ-phylogenetic tree. Three unique point substitutions at the N-terminus of the molecule, Arg1,
Gly2, and Ser5, distinguish HCRG21 from other peptides of this cluster. The trypsin inhibitory
activity of recombinant HCRG21 (rHCRG21) was comparable with the activity of peptides from
the same cluster. Inhibition constants for trypsin and α-chymotrypsin were 1.0 × 10−7 and
7.0 × 10−7 M, respectively. Electrophysiological experiments revealed that rHCRG21 inhibits 95% of
the capsaicin-induced current through transient receptor potential family member vanilloid 1 (TRPV1)
and has a half-maximal inhibitory concentration of 6.9 ± 0.4 µM. Moreover, rHCRG21 is the first full
peptide TRPV1 inhibitor, although displaying lower affinity for its receptor in comparison with other
known ligands. Macromolecular docking and full atom Molecular Dynamics (MD) simulations of the
rHCRG21–TRPV1 complex allow hypothesizing the existence of two feasible, intra- and extracellular,
molecular mechanisms of blocking. These data provide valuable insights in the structural and
functional relationships and pharmacological potential of bifunctional Kunitz-type peptides.
Keywords: sea anemone; Cnidaria; TRPV1; Kunitz-type peptides; electrophysiology
1. Introduction
Sea anemone (phylum Cnidaria, class Anthozoa) venom is a rich source of proteinaceous toxins
acting on ion channels such as voltage-gated sodium and potassium channels, and the TRPV1 [1–5]
as well as a lot of protease inhibitors belonging, mainly, to a numerous BPTI/Kunitz-type family [6].
The peptides of this family have an ancient Kunitz fold and some of them are characterized by a unique
and intriguing feature of dual functionality since they inhibit both proteases and ion channels [7–10].
This phenomenon is probably caused by the selection of peptide structures during divergent evolution
together with specialization, diversification and sub- and neofunctionalization [11]. Considering an
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increasing diversity in sea anemone preys and predators, more than one function in the same peptide
scaffold is advantageous for the survival of these organisms on Earth for nearly 500 million years [12].
It is believed that Kunitz peptides in sea anemone venom protect the own toxins from protease
degradation and at the same time, paralyze a prey through inhibition of ion channels [9,10].
To date, a number of highly homologous native serine protease inhibitors has been isolated from
different species: Anemonia sulcata [7,13], Heteractis crispa [14–18], Anthopleura aff. xanthogrammica [19,20],
Anthopleura fuscoviridis [21], Stichodactyla helianthus [22–24], and Stichodactyla haddoni [8]. Three
Kunitz-type protease inhibitors, first representatives of bifunctional molecules, AsKC1–AsKC3 [7],
SHTX III [8], APEKTx1 and ShPI-1 [9,10], belonging to the structural type 2 sea anemone toxins, have
been shown to exhibit both a powerful blocking activity against voltage-gated potassium channels and
a serine protease inhibitory activity. Moreover, ShPI-1 has broad protease inhibitory specificity as it
inhibits not only serine but also cysteine and aspartate proteases [22].
It was found that H. crispa Kunitz-type protease inhibitors are coded by the multigene superfamily
and form a combinatorial library including HCGS, HCRG, HCGN, and HCGG peptide subfamilies [11].
The HCGS peptide subfamily and their evolutionary relationships were described in details
previously [11,25]. Two sea anemone trypsin inhibitors, RmInI and RmInII, possess antihistamine
activity in vivo [15]. Recently, we have shown that rHCGS1.20 has an anti-inflammatory activity
thanks to its ability to reduce the content of nitric oxide (NO) in lipopolysaccharide activated
macrophages. Moreover, this peptide, as well as rHCGS1.19 and rHCGS1.36, possess antihistamine
activity by inhibiting the increase of the concentration of calcium ions in mouse bone marrow derived
macrophages [26,27]. HCRG1 and HCRG2 are the first two representatives of a new Kunitz-type HCRG
peptide subfamily [18]. These peptides are more potent inhibitors of trypsin and α-chymotrypsin
than some known representatives of the HCGS subfamily [14,16,17] and they have exhibited an
anti-inflammatory activity through inhibition of inflammatory mediators [18].
It was also found that three H. crispa serine protease inhibitors, APHC1, APHC2, and APHC3,
possess an analgesic activity [28–31] by exhibiting an inhibitory activity against the pain receptor
TRPV1 [28,32]. They are the first sea anemone peptide characterized as TRPV1 modulators. APCH1
decreases the capsaicin induced currents through TRPV1 with 32% ± 9% (EC50 = 54 ± 4 nM) [28].
Interestingly, the pharmacological potential of APHC1 and APHC3 can be considerably expanded by
their hypothermic effect [30], which is not typical for low molecular weight TRPV1 antagonists.
Among all known ion channels involved in the regulation of a variety of intracellular signaling
pathways, perception, and conduction of pain signals in dorsal root ganglia (DRG) neurons, an
important integrator of painful and inflammatory stimuli is the TRPV1 receptor [33,34]. It belongs to the
family of polymodal TRP channels, serving as a molecular cellular sensor, which is activated by a wide
spectrum of physical and chemical stimuli [35–37]. They have diverse biophysical properties such as
cation selectivity, specific mechanisms of activation, and they play the main role in many physiological
processes—fertilization, development, cell survival, sensory transduction, etc. [38,39]. The TRPV1
receptor is a promising biological target for searching new analgesic agents as well as therapeutic target
for various pain states [33,36,37,40]. It is believed that, unlike traditional analgesic agents (aspirin,
paracetamol/acetaminophen, and other non-steroidal anti-inflammatory drugs) that suppress or
treat inflammatory processes or the transmission of pain signals, TRPV1 antagonists prevent pain by
inhibiting the receptor on susceptible neurons [41,42]. Currently, many low molecular weight TRPV1
agonists as well as antagonists have been studied [43] (some of them are already used or will be
used in clinical practice [44,45]). It should be noted that the use of TRPV1 antagonists as analgesic
agents until now is hindered by their significant side effects, mainly propensity to induce hypothermic
effects [41,42,44]. Notably, abundant scientific research has focused on the development of approaches
to overcome these side effects. Focusing on the nature of the TRPV1 receptor itself—multimodality
with respect to different stimuli and the selection of successful combination of such factors of TRPV1
regulation as antagonist, effective dose, pH, temperature control, way of delivery, etc. [46,47]—will
certainly contribute to the progress in developing antagonists suitable for clinical practice. There are
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only five venom-derived peptides acting on TRPV1 known up to date. A double-knot toxin DkTx,
from the Chinese bird spider Ornithoctonus huwena [48], the toxins VaTx1–VaTx3 from the tarantula
Psalmopoeus cambridgei [49], and BmP01 from the scorpion Mesobuthus martensii [50] are agonists,
while APHC1–APHC3, from the sea anemone H. crispa, are three partially antagonists of the TRPV1
receptor. [28,30,31]. Sea anemone Kunitz-type peptides can be considered as a valuable instrument for
studying the structure and function of TRP channels and as a template for designing novel analgesic
agents [30].
Here, we describe a new Kunitz-type bifunctional peptide, representative of the H. crispa HCRG
peptide subfamily, which is the first full antagonist of TRPV1 receptor.
2. Results and Discussion
2.1. cDNA hcrg21 Gene and Recombinant Peptide Obtaining
To study structural diversity of a new HCRG peptide subfamily, a combinatorial library of HCRG
peptides was obtained [51]. Here for, nested PCR with gene specific primers created on the basis of
nucleotide sequences of Kunitz-type peptide genes was used [11] (Table S1). Analysis of the deduced
amino acid sequences revealed that all peptides have a N-terminal Arg1 and Lys14 at the P1 position.
However, one unique peptide, HCRG21, has Thr14 at this position, similar to the representatives of so
named “analgesic cluster” of HCGS peptide subfamily have. This cluster is composed of analgesic
peptides APHC1–APHC3 which are also known as modulators of the TRPV1 receptor [28,30–32].
HCRG21 shares 82% to 95% of identity with APHC1–APHC3, as well as with Jn-IV, InhVJ, and some
HCGS peptides deduced by the PCR-based cloning technique (HCGS1.10, HCGS1.34, HCGS1.36,
HCGS1.26, and HCGS2.3) (Figure 1a) [11]. All these peptides slightly differ from each other. Therefore,
it is not surprising that, according to phylogenetic analysis, HCRG21 clusters with the analgesic
peptides but forms a separate branch on the neighbor-joining (NJ) phylogenetic tree (Figure 1b).
It should be noted that three unique point substitutions at the N-terminus of the molecule, Arg1, Gly2,
and Ser5, differ between HCRG21 and other peptides of this cluster.
Moreover, HCRG21 is highly homologous, 84% of identity, with ShPI-1, a protease inhibitor from
the sea anemone S. helianthus, which binds with high affinity to Kv1.1, Kv1.2, and Kv1.6 channels [10].
For many potent Kv channel blocking toxins, such as α-DTX, DTX-K, and DTX-I, isolated from the
snake Dendroaspis polylepis, it has been well established that mainly a series of positive charged residues
(for example, R3, R4, K5, K37, K39, K46, and K50 in α-DTX) are crucial for interaction with the Kv
channel [52–54]. In addition, for Kv channel toxins from sea anemones, such as the kalicludines from
A. sulcata, AsKC1 and AsKC2, a N-terminal dyad (K3/L7 in AsKC1 and AsKC2) together with a number
of non-polar residues have been identified as important for peptide binding with the channels [7].
Amino acid sequence alignment of Kv blockers from the snake, α-DTX, DTX-K, and DTX-I, and the sea
anemones, ShPI-1 and AsKC1, and HCRG21 (Figure 1c) demonstrates the presence of positive charged
residues (8 in HCRG21 and ShPI-1, 10 in AsKC1, in comparison with 11 in DTX-K and 14 α-DTX, and
DTX-I) located not only at the N- and C-terminus, but throughout the whole sequence.
















Nodes  with  confidence  values  greater  than  30%  are  indicated;  (c)  Comparison  of  amino  acid 
sequences of H. crispa HCRG21, ShPI‐1 from S. helianthus [22], AsKC1–AsKC3 from A. sulcata [7] and 
α‐DTX, DTX‐K,  and DTX‐I  from  the  snake  Dendroaspis  polylepis  [53].  Identical  and  conservative 
residues  are  indicated  by dark  and  light  gray  colors,  respectively. Positive  charged  residues  are 
colored in blue.   
Figure 1. (a) Alignment of H. crispa Kunitz-type peptides amino acid sequences. Analgesic peptides,
APHC1, APHC2, APHC3 [28,29], Jn-IV [14], InhVJ [16], and representatives of HCGS peptide family
with P1Thr from the combinatorial library, obtained from H. crispa cDNA [11]: HCGS1.10, HCGS1.36,
HCGS1.34, HCGS1.26, and HCGS2.3; and BPTI from bovine pancreas [55]. P1—amino acid residue
of the inhibitor reactive center. Identical and conservative residues are indicated by dark and light
gray colors. The asterisks below the sequence of BPTI indicate the contact sites with serine proteases;
(b) Evolutionary relationships of H. crispa sea anemone Kunitz-type peptides. The NJ phylogenetic tree
was made using the Poisson correction with bootstrap test of 1000 replications in MEGA 6 [56]. Nodes
with confidence values greater than 30% are indicated; (c) Comparison of amino acid sequences of
H. crispa HCRG21, ShPI-1 from S. helianthus [22], AsKC1–AsKC3 from A. sulcata [7] and α-DTX, DTX-K,
and DTX-I from the snake Dendroaspis polylepis [53]. Identical and conservative residues are indicated
by dark and light gray colors, respectively. Positive charged residues are colored in blue.
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Based on its sequence, HCRG21, could exhibit protease, Kv and/or TRPV1 inhibitory
blocking activity. To verify this assumption, the recombinant peptide, rHCRG21, was obtained and
functionally tested.
Figure 2 shows the hcrg21 cDNA including an open reading frame of 234 bp, which encodes
56 amino acids of the mature peptide, and a hcrg21 gene synthesis scheme. The synthesis of the hcrg21
gene was carried out by two PCR rounds using gene specific primers created on the basis of the
nucleotide sequence with optimized codons according to E. coli rare codons (Table S1). rHCRG21 was
produced as a fusion protein with a thioredoxin (Trx) domain with a molecular mass of about 25 kDa
(according to electrophoresis data) and isolated from culture medium by metal affinity chromatography,
cleaved by cyanogen bromide (CNBr), and purified by HPLC. The yield of the recombinant peptide
was 5.5 mg/L of the cellular culture. Trypsin inhibitory activity was detected in the fraction marked
rHCRG21 (Figure 3). According to MALDI-TOF/MS analysis, the molecular mass of rHCRG21 yielded
6228.12 Da (Figure 3 insert) which corroborated well the calculated theoretical mass when considering








gene was carried out by  two PCR  rounds using gene specific primers created on  the basis of  the 
nucleotide sequence with optimized codons according  to E. coli rare codons  (Table S1). rHCRG21 
was produced as a fusion protein with a thioredoxin (Trx) domain with a molecular mass of about 25 
kDa  (according  to  electrophoresis  data)  and  isolated  from  culture  medium  by  metal  affinity 
chromatography,  cleaved by  cyanogen bromide  (CNBr), and purified by HPLC. The yield of  the 
recombinant peptide was 5.5 mg/L of the cellular culture. Trypsin inhibitory activity was detected in 
the  fraction marked  rHCRG21  (Figure  3). According  to MALDI‐TOF/MS  analysis,  the molecular 








protein  Trx‐HCRG21  by  BrCN,  on  a  Jupiter  C4  column  (Phenomenex,  Torrance,  CA,  USA), 
equilibrated  by  0.1%  TFA,  pH  2.2,  (Solution  A),  in  a  gradient  of  acetonitrile  (Solution  B) 
concentration (0%–70%) for 70 min at 3 mL/min. Fractions containing the mature peptide rHCRG21 
are underlined. Insert: MALDI‐TOF/MS spectrum and molecular mass of rHCRG21 after RP‐HPLC. 
Figure 2. The hcrg21 gene sequence and the deduced amino acid sequence of HCRG21. The arrows
show the direction and length of the primers used for gene synthesis. The digits on the right show the
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protein  Trx‐HCRG21  by  BrCN,  on  a  Jupiter  C4  column  (Phenomenex,  Torrance,  CA,  USA), 
equilibrated  by  0.1%  TFA,  pH  2.2,  (Solution  A),  in  a  gradient  of  acetonitrile  (Solution  B) 
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Figure 3. The RP-HPLC elution profile of rHCRG21, obtained as the result of hydrolysis of the fusion
protein Trx-HCRG21 by BrCN, on a Jupiter C4 column (Phenomenex, Torrance, CA, USA), equilibrated
by 0.1% TFA, pH 2.2, (Solution A), in a gradient of acetonitrile (Solution B) concentration (0%–70%)
for 70 min at 3 mL/min. Fractions containing the mature peptide rHCRG21 are underlined. Insert:
MALDI-TOF/MS spectrum and molecular mass of rHCRG21 after RP-HPLC.
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2.2. Comparison of Kunitz-Type Inhibitors Protease Inhibiting Activity
Similar to the most potent trypsin inhibitor, BPTI, many sea anemone peptides are very active
towards trypsin because of the presence of functionally important P1 Lys or Arg residues at their
reactive sites located at the canonical binding loop [57]. It is shown, that the first known H. crispa
analgesic Kunitz-type peptides, APHC1–APHC3, have a Thr residue (instead of Lys or Arg) at position
P1, similar to other representatives of the analgesic cluster (Figure 1a,b). Inhibition constants (Ki) of
rHCRG21 for trypsin and α-chymotrypsin determined by the Dixon method yielded 2.0 × 10−7 and
7.0 × 10−7 M, respectively (Table 1). It is known that interactions between trypsin-like proteases and
serine protease inhibitors having branched residues, such as Thr, Val, or Ile, located at the P1 position
is not favorable [58,59]. Therefore, in contrast with the affinity of BPTI to trypsin, many sea anemone
Kunitz-type inhibitors such as InhVJ, Jn-IV, and APHC1–APHC3 display a (Figure 1b) significantly
lower potency (in the range of Ki values 10−6–10−9 M). As such, the trypsin inhibitory activity is in line
with other peptides of this subfamily. The constant values of trypsin inhibition for rHCRG21, APHC2
(9.0 × 10−7 M), and APHC3 (5.0 × 10−7 M) [29] are of the same magnitude orders. Nevertheless,
a slightly higher value of Ki for rHCRG21 compared to those of APHC1–APHC3, can be explained
by the presence of a N-terminal Arg, which noticeably increases the energy of Kunitz-type H. crispa
peptides binding with proteases. This energy benefit has been shown previously by computational
methods for HCRG1 and HCRG2 [18] (Table 1).
At the same time, according to the previously proposed hypothesis [11], replacement of residues
at position P1 (Arg→ Lys→ Thr) during evolution has resulted, along with the specialization of some
Kunitz-type peptides, into diversification and sub- and neofunctionalization of ancestral peptides of
this superfamily. Furthermore, it allowed the appearance of peptides with dual functionality, e.g., Kv
and TRPV1 channel inhibitory activity together with trypsin inhibitory activity.
Table 1. Physical and chemical characteristics of some native sea anemone BPTI/Kunitz-type canonical
inhibitors and rHCRG21.
Sea Anemone Peptide Mr, Da P1 Residue
Ki, M
Trypsin α-Chymotrypsin
Bos taurus BPTI [55] K 6.0 × 10−14 1.8 × 10−13
A. sulcata
AsKC1 [7] 6685 *
R
<3 × 10−10 n.d.
AsKC2 [7] 6772 * <3 × 10−10 n.d.
AsKC3 [7] 6732 * <3 × 10−10 n.d.
SA5 II [13] 6937 ** 3.0 × 10−10 n.d.
A. elegantissima APEKTx1 [9] 7469 * 1.2 × 10−7 * n.d.
S. helianthus
SHPI-1 [23] 6110 *
K
1.1 × 10−10 2.3 × 10−9
SHPI-2 [23] 6195 ** 3.8 × 10−10 n.d.
H. crispa HCRG1 [18] 6196 * 2.8 × 10
−8 n.d.




2.0 × 10−7 7.0 × 10−7
Jn-IV [14] 6165 * 9.6 × 10−9 n.d.
InhVJ [17] 6106 * 7.38 × 10−8 9.93 × 10−7
APHC1 [28] 6187 * 1.0 × 10−6 5.0 × 10−6
APHC2 [29] 6185 * 9.0 × 10−7 4.5 × 10−6
APHC3 [29] 6111 * 5.0 × 10−7 7.0 × 10−6
* MALDI-TOF/MS analysis data; ** UniProt data; n.d.: not determined.
2.3. Activity to Kv and TRPV1 Channels: Electrophysiological Assay and Comparative Structure Analysis
In order to characterize HCRG21 functionally, recombinant HCRG21 was, at a concentration of
10 µM, tested for its activity against an 8 voltage-gated potassium channels (Kv1.1–Kv1.6, hERG, and
Shaker IR) and the vanilloid receptor 1 (TRPV1).
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However, rHCRG21 did not exert any activity on the Kv channels tested (Figure 4). Although there
are many positively charged residues present in the sequence of HCRG21, they do differ in position
with known Kv1.1–Kv1.6 blockers, such as α-DTX, DTX-K, DTX-I, AsKC1, and ShPI-1 (Figure 1c).
Previously, an absence of Kv channel activity was also observed for the InhVJ [17]. Noteworthy, several
positively charged residues are conserved between HCRG21 and ShPI-1 (in positions 8, 19, 28, 51,
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effect  (Figure  5a).  Similarly,  no  activity  was  seen  when  HCRG21  was  applied  prior  to  any 
stimulation of capsaicin (data not shown). However, when rHCRG21 was co‐applied together with 
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APHC1, which  inhibits TRPV1 only partially  (the highest percentage of  inhibition obtained was 
~50% [28]), there was almost full inhibition of the current through TRPV1 with a maximum observed 
inhibition of 95% (Figure 5c).   
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Figure 4. Activity of rHCRG21 on Kv channels expressed in X. laevis oocytes. Traces shown are
representative of at least three independent experiments (n ≥ 3). The dotted line indicates the zero
current level. The asterisk (*) isti is es t e stea -state c rre t after a licati f 10 µ e ti e.
To control the expression level of the TRPV1 channels, experiments were initiated with a first
activation of TRPV1 with 1 µM capsaicin (CAP). Application of capsaicin opens the channels. This
activation gives an inward non-selective cation current. Subsequent application of capsazepine (CZP)
closes the channels allowing the current levels to return to zero. Before application of HCRG21, cells
are washed with ND96 to remove any presence of capsazepine. As for the interaction of rHCRG21
with TRPV1, when peptide was administered alone, it did not show any significant effect (Figure 5a).
Similarly, no activity was seen when HCRG21 was applied prior to any stimulation of capsaicin
(data not shown). However, when rHCRG21 was co-applied together with the agonist capsaicin, a
reduction of the current was observed (Figure 5b). Application of 10 µM rHCRG21 caused an inhibition
with 59.3% ± 4.3% (n ≥ 3). A concentration–response curve was constructed in order to assess
the concentration dependence of the rHCRG21 induced effect. The IC50 value yielded 6.9 ± 0.4 µM
(Figure 5c). Although rHCRG21 has apparently lower affinity than APHC1, which inhibits TRPV1 only
partially (the highest percentage of inhibition obtained was ~50% [28]), there was almost full inhibition
of the current through TRPV1 with a maximum observed inhibition of 95% (Figure 5c).
The difference in efficacy between rHCRG21 and APHC1 on TRPV1 (95% and 50% receptor
inhibition, respectively) seems to result from small differences in functionally important basic residues
within the sequence of both peptides. Previously, on the basis of experimental data [28] and computer
modeling [32], it was suggested that the most functionally important residues are Glu6, Thr14, Val31,
Glu38, Arg48, and Arg51 in APHC1. All these residues are conserved between APHC1 and HCRG21,
except Val31, which is replaced by a Pro in HCRG21. It is well known that prolines can induce a
structural kink in a peptide structure. It is possible that the Val31 to Pro substitution in HCRG21 results
in a conformational change that allows HCRG21 to expose a contact surface differing from that of
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APHC1, which might explain the differences in efficacy between these peptides. However, detailed
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Figure 5. Activity profile of rHCRG21 (10 µ ) on the TRPV1 receptor. The figures show the results
of one representative experi ent. hole-cell current traces in control and rHCRG21 conditions are
sho n. (a) Lack of effect of r CRG21 (10 µ ) in the absence of capsaicin; (b) Antagonistic effect of
CR 21 co-applied ith capsaicin (CAP = 2 µM); capsazepine (CZP = 10 µM). All data represent the
average of at least three independent experiments (n ≥ 3) and are presented as mean ± standard error;
(c) Concentration–response curve for rHCRG21 on TRPV1 receptor.
2.4. Molecular Modeling
In this paper, we continued the study of the ligand-receptor interaction between HCRG21 and
TRPV1 in order to clarify the mechanism of HCRG21 action. Application of modern bioinformatic
approaches and programs of molecular modeling (molecular docking and MD simulations) allows
to set clear patterns and to speculate about the subtle intermolecular interactions of ion channel or
receptor and their antagonists/agonists, which represents the basis for the creation of novel selective
pharmacophores for these targets.
Earlier, we have made an attempt to understand the mechanism, underlying the action of APHC1
from H. crispa on capsaicin-induced currents through the TRPV1 channel. Based on the homology
model, we have made a conjecture that APHC1 may interact with the regulatory domain of intracellular
receptor portion [60]. According to this model, a modulating effect of the peptide can be explained
by its interaction with multiple (two or more) subunits of the regulatory receptor domain, which
prevents its free transition from one state to another, and apparently extends the receptor relaxation
time. Analysis of the architecture of the HCRG21 complex with the intracellular part of the receptor,
derived from APHC1–TRPV1 complex [32] by homology docking and MD simulations have revealed
that 26 HCRG21 residues, including Thr14, Tyr16 and Phe17, differing peptides of “analgesic cluster”
(Figure 1b) from other H. crispa Kunitz-type peptides, are involved into hydrogen bonding and/or
electrostatic interactions as well as pi-interactions with all receptor subunits (in total 57 interactions,
Table S2).
In agreement with this hypothesis, Arg1 contributes to binding energy of −20.1 kcal/mol
compared to −10.7 kcal/mol for Gly1 of APHC1 (Figure 6a,b). In addition to backbone H-bonding
and salt bridging to Glu812, its long basic and flexible side chain forms 4 hydrogen bonds to Gln817
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and Asn756 of receptor subunit B. Contribution of HCRG21 Ser5 H-bonds to binding energy with
Glu812 and Glu762 of the same receptor subunit was estimated as −2.8 kcal/mol. This observation
clearly evidenced that replacement of Gly1 to Arg and Ley5 to Ser in HCRG21 further to Arg51 and
Arg55 of APHC1 (and other analgesic peptides) enables HCRG21 to bind more tightly (compared
to APHC1) the adjacent subunits of the receptor regulatory domain by two polar fingers (Figure 6c).
This interaction manner is very similar to the one of DkTx, this peptide binds with the extracellular part
of the receptor by hydrophobic aromatic fingers [61]. However, unlike the agonist DkTx, which causes
a conformational change in the receptor upper pore region and enhances the ion current through the
channel, HCRG21, most likely, hampers the transition of the receptor into another state and hereby
the availability of the receptor for a following pain signal. This model obviously requires additional
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represented  as  a  ribbon,  residues  of  both  peptides  and  receptor  involved  in  interactions  are 
represented as  sticks and colored according  to  subunits: direct hydrogen bonds  colored  in green; 
electrostatic and π‐cation interactions in light brown; and hydrophobic interactions in magenta.   
This model  is  in good agreement with  the analgesic action of “analgesic cluster” peptides  in 
vivo  that was demonstrated  to be developing during 1–3 h  [25,28]. Furthermore, a model of slow 
Figure 6. Molecular model of HCRG21 interaction with TRPV1 intracellular portion. 2D diagram of
HCRG21 N-terminal residue interaction to TRPV1: (a) Arg1 of HCRG21; (b) Gly1 of APHC1; and
(c) ribbon diagram of HCRG21 intermolecular interactions with TRPV1 regulatory domain. HCRG21 is
represented as a ribbon, residues of both peptides and receptor involved in interactions are represented
as sticks and colored according to subunits: direct hydrogen bonds colored in green; electrostatic and
pi-cation interactions in light brown; and hydrophobic interactions in magenta.
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This model is in good agreement with the analgesic action of “analgesic cluster” peptides in vivo
that was demonstrated to be developing during 1–3 h [25,28]. Furthermore, a model of slow interaction
also agrees with the data regarding kinetics of vanilloids penetration into the cell (equilibrium is
reached near to 2 h) and herewith a dramatic decreasing of effective ligand concentration (by two orders
of magnitude at 2 h of pre-incubation conditions) when compared to simultaneous application [62].
In the past four years, great progress has been made in the capabilities of cryoelectron microscopy.
This provided new knowledge on the spatial organization of the extracellular and transmembrane
domains of TRPV1 in absence of ligands, as well as in the low molecular agonist- and peptide
agonist-bound states [61]. However, the available information about the rat TRPV1 minimal active
fragment is still not enough for comprehension of how peptide antagonists or blockers may affect the
receptor kinetics. For a deeper understanding of a possible mode of action of peptides on the pain
vanilloid receptor, we performed a molecular modeling by exploring techniques of macromolecular
docking and MD simulations.
According to generated models, HCRG21 may bind in the area of the outer vestibule of the TRPV1
channel pore (Figure 7a). The peptide binding site does not overlap with known binding sites of
vanilloids or small molecule agonists and antagonists. However, it is localized in close proximity to
the binding site of the spider peptide toxin, DkTx, which binds with TRPV1 outer pore domain [48].
According to our docking data, Arg1, Arg18, and Lys28 of HCRG21 overlap with DkTx binding site
only at the area of Glu651 residues of the TRPV1 receptor (Figure 7a).
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and  colored  according  to  receptor  subunits,  HCRG21  residues  colored  in  light  brown. 
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Figure 7. Structure model of complex of HCRG21 with TRPV1 receptor. (a) Superposition of
HCRG21–TRPV1 complex to crioelectron microscope 3D-structure complex of DkTx with the receptor
5IRX [61]. Glu651 represented as bolds and colored according to elements, DkTx molecular surface is
colored in gray, point distribution of molecular electrostatic potential (MEP) for HCRG21 molecule
are presented; (b–e) Diagram of intermolecular non-bonded interactions in HCRG21–TRPV1 complex,
several critical residues described in the text are represented as sticks and colored according to
receptor subunits, HCRG21 residues colored in light brown. Intermolecular interactions as well as
intramolecular ones are represented as dashed line and colored: hydrogen bonds in green; electrostatic
and pi-cation interactions in light brown; and hydrophobic in light magenta; (f) TRPV1 outer pore
formed by Met644 residues in the TRPV1 complex with HCRG21 revealed by MD simulations. TRPV1
subunits are represented as a ribbon diagram and colored according to chain; side chains of Met644 are
represented as sticks and colored according to elements; hydrogen bonds between adjacent receptor
subunits are represented as blue dashed line; distance between Met644 side chains of opposite TRPV1
subunits is indicated; (g) The role of HCRG21 basic and acidic residues in interaction with TRPV1 pore
and turret regions. HCRG21 is presented as ribbon diagram (light brown color) and molecular surface
(light gray color), charged residues surfaces are colored according to extrapolated charge, positive in
blue, negative in red. TRPV1 presents as ribbon diagram and colored in green. Localization of key
TRPV1 turret and lining the pore residues involved into HCRG21 interaction is presented as bolls and
marked by o e letter amino acids code.
The N-terminal polar residue Arg1 of HCRG21 binds tightly to both Phe649 and Glu651 of one
subunit through multiple H-bonding and salt bridges with an estimated contribution to the binding
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energy of −12.27 kcal/mol and −16.82 kcal/mol, respectively. After MD simulations nearby Lys622
became bound to both Glu651 and Glu648 of adjacent subunit through hydrogen bond and strong
ionic interactions. One can assume Arg1 to provide conformation of pore loop that allows acidic side
chains of Glu651 and Glu648 to interact firmly (−43.10 kcal/mol) with the extracellular loop 3 through
Lys622. At the same time the Gly2 backbone forms hydrogen bond with Cys621 of the same receptor
subunit (Figure 7b). Probably this structural rearrangement highlights the role of the 1RG2 fragment,
preventing the capsaicin provoked conformational changes at the pore loop region. From the other side,
in a similar fashion, a basic Lys28 side chains of HCRG21 can electrostatically interact with Asp601 and
Glu651 ones in addition to hydrogen bond with the Phe649 carbonyl oxygen of the opposite receptor
subunit (Figure 7c) resulting in a total contribution to the binding energy of −10.19 kcal/mol. Beside
this Arg51 brings the outer mouth of the channel pore through strong electrostatic interaction and
hydrogen bonding with Glu636 (−18.29 kcal/mol) of the same subunit. Moreover, both Lys28 and
Arg51 anchored strongly enough (with a total contribution of −9.70 kcal/mol) in the mouth of the
pore by means of formation of pi-interactions cluster across the Phe649 aromatic ring (Figure 7c).
According to this model, Arg48 of HCRG21 binds firmly two other TRPV1 subunits in the region
of mouth of the pore by two H-bonds and multiple attractive electrostatic interactions with each of
three acidic residues Glu648 (−22.76 kcal/mol) and Asp646 (−21.13 kcal/mol) of one receptor subunit
as well as with Glu636 (−20.47 kcal/mol) of adjacent subunit (Figure 7d). At the same time, the Arg48
backbone is localized near the TRPV1 pore and can form a hydrogen bond with Met644 residue of
third receptor subunit creating difficulties for an intracellular ion influx. It should be noted that the
Glu648 residues are responsible for TRPV1 proton binding [63]. Interestingly, we have demonstrated
previously that in contrast to APHC1 and HCRG21, peptide InhVJ, with Arg48 substituted by His, is
inactive on the TRPV1 channel when co-applied with capsaicin [17]. In agreement with computational
data, binding of InhVJ would bring a His residue in close proximity with receptor proton binding site
(Glu648). Therefore, InhVJ could be a potential modulator of TRPV1 depending on the protonation
state of His48 which is strongly depending on the environment.
MD simulations of the HCRG21–TRPV1 complex in a hydrated 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine (POPC) lipid bilayer showed that HCRG21 interaction with the extracellular portion of
the receptor may cause a change in conformation in the area of the pore at the upper gate. Furthermore,
it suggests a displacement of the pore loop (helix 630–642) and γ-turn 643–651 with RMSD ~1.68 Å
for 22 Cα-atoms. Unlike the experimental frozen receptor structure, these rearrangements in the
structure of the selectivity filter during MD simulations are not symmetrical among subunits. At the
same time, this observation is consistent with reported results of a long microsecond time scale
(1 µs) MD simulations of temperature activated TRPV1 [64]. MD simulations revealed that, upon
complex formation with HCRG21, conformational changes in the pore loop region of the channel occur.
These structural changes bring the side chains of Met644, which form the outer pore, in a sufficient
close proximity (Figure 7e) to form hydrogen bonds (3.93 Å), that is not observed in a non-conducting
receptor state (PDB ID: 3J5P). In the activated state of the channel, no intra- or inter-H-bonding in
the pore helices are normally present [65,66]. Moreover, Ala52 of HCRG21 as well as methylene
groups (-CH2-) of Arg48, Arg51, and Arg55 cooperate with Met644 residues from three channel pore
loops to form a hydrophobic seal. Their contributions to complex stabilization were estimated at
−1.91 kcal/mol, −1.57 kcal/mol, −1.45 kcal/mol, and −0.45 kcal/mol, respectively. As a result the
solvent availability of residues forming the pore upper gate decreases from 25% in activated state to
10% in complex with HCRG21. This low solvent availability of the receptor pore agrees well with
electrophysiological data on rHCRG21 action (Figure 7f).
MD simulations data showed also the role of acidic HCRG21 residues Glu25, Glu38, and Glu45
that seems like to interact with the TRPV1 pore turret (Figure 7f). These flexible extracellular loops
were not determined experimentally but a pool of biochemical data evidenced its significance for
TRPV1 responses on diverse stimuli [67,68]. Notably, these long extracellular loops that form TRPV1
pore turret and are directly linked to the channel pore helix represent a highly variable region among
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TRPV family members. The basic residues occurrence at the top of the turret (Lys615, Arg617, and
Lys622) is characteristic for TRPV1 cannel isoform. These residues are omitted or replaced to neutral
or acidic ones in other TRPV channels isoforms, except in human TRPV3 with only Lys622 in this
loop [65].
Therefore, our modeling reconstruction confirms the crucial importance of positively charged
residues ring (Arg1, Arg18, Lys 28, Arg48, Arg51, and Arg55) for HCRG21 action on current flow
through ion channels that is discussed widely for those of Kv1 toxins [9,10,69]. Moreover, we ascertain
the putative role of negatively charged residues in peptide antagonist interaction with TRPV1 channel.
The former interact with acidic residues lining the TRPV1 pore and might penetrate deeply to the
outer pore down to the close proximity for Met644 selective filter. The later possibly stabilize the
complex by additional interaction of peptide antagonist with the TRPV1 extracellular loops 3, carrying
a positive charge in the turret region (Figure 7g). The proposed model agrees with experimental data
that rHCRG21 could fully inhibit the TRPV1 receptor with a maximum observed inhibition of 95%.
In our computational simulations, we observed multiple interactions of peptide residues except Thr14
or Tyr16 with the residues of TRPV1 subunits at the outer vestibule. So, it remains unclear why
the Thr residue at P1 position is of crucial importance for peptides of H. crispa “analgesic cluster”
(Figure 1b). It should be also noted that peptides of this cluster unlike other members of HCGS and
HCRG subfamilies have a very small net positive charge of the molecule (in range from 0 to +2) [32].
Moreover, they are characterized by a point distribution of the MEP [11,32]. It can be assumed
that the specificity of a peptide modulator for its target may be well determined by the electrostatic
complementarity between both. In this respect, the combinatorial library of H. crispa, which provided
several Kunitz-type peptides with variations of single charged residues in their sequence, serves as
a promising source of peptides specific to different receptor subtypes and various types of stimuli.
Therefore, HCRG21 represents a promising tool for studying TRPV1 channels and, moreover, might be
an interesting lead compound for the development of novel analgesics.
3. Materials and Methods
3.1. Gene Sequence Determination
cDNA library of Kunitz-type HCRG peptides was obtained by nested PCR (two round) with
gene specific primers, created on the base of obtained nucleotide sequences of Kunitz-type peptide
genes previously [11]. H. crispa cDNA obtained as reported [70] was used as matrix. The primer
sequences and PCR conditions are shown in Table S1. The standard methods were used for cloning
obtained PCR-fragments (~180 bp) and plasmid isolation [71]. Analyses of the nucleotide sequences
of the inserts were performed on an ABI3130xl genetic analyzer (Applied Biosystems, Foster City,
CA, USA) [72].
3.2. Synthesis of Gene Encoding HCRG21
Synthesis of the hcrg21 gene was carried out by PCR (2 steps) using gene specific primers created
on the base optimized according to rare codons for E. coli expression hcrg 21 gene (Table S1). Expression
construction was created by cloning the gel-purified PCR-fragment (~180 bp) into vector pET-32b(+)
(Novagen) at the EcoRI and XhoI restriction sites by standard methods [71]. The resulted construct
was checked by sequencing. The nucleotide and deduced amino acid sequences were analyzed using
the Vector NTI 8 software package (Invitrogen, Grand Island, NY, USA).
3.3. Production and Physical and Chemical Characterization of Recombinant HCRG21
The transformed cells were cultured in LB medium (1 L) containing ampicillin (100 µg/mL)
at 37 ◦C to the optical density of A600 0.6–0.8. Isopropyl-β,D-thiogalactopyranoside (IPTG) was
added to the final concentration of 0.2 mM for the expression induction. The cells were grown for
16–18 h at 18 ◦C for the production of the recombinant peptide in a soluble form. The bacterial cells
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were precipitated from the solution by centrifugation at 8000 rpm for 8 min. The hybrid protein
that contained thioredoxin and HCRG21 peptide was isolated by the metal affinity chromatography
on the Ni-NTA-agarose in the native condition from the soluble fraction of the cellular lysate after
its ultrasound treatment according to the manufacturer’s instruction. Thioredoxin was cleaved by
the treatment with cyanogen bromide according to the modified technique [73]. The recombinant
HCRG21 peptide was purified by the reversed phase HPLC on a Jupiter C 4 column (10 × 250 mm,
Phenomenex, Torrance, CA, USA), equilibrated by 0.1% TFA, pH 2.2, (Solution A), in gradient of
acetonitrile (Solution B) concentration (0%–70%) for 70 min at 3 mL/min. The retention time of the
target product was 31 min.
MALDI-TOF/MS spectrum of rHCRG21 was recorded using an Ultra Flex III MALDI-TOF/TOF
mass spectrometer (Bruker, Bremen, Germany) with a nitrogen laser (SmartBeam, 355 nm), reflector
and potential LIFT tandem modes of operation. Sinapinic acid was used as a matrix. An external
calibration was employed using a polypeptide sample [17] with m/z 6107 and its doubly-charged
variant at m/z 3053.
Homology sequence analysis was carried out using protein databases and BLAST programs [74].
The nucleotide sequence data of hcrg21 reported in this paper will appear in the GenBank under
the accession numbers KX900498. The accession numbers of the peptide sequences are InhVJ (UniProt
KB P0DMJ5); Jn-IV (UniProt KB P16344); APHC1, APHC2, and APHC3 (UniProt KB B2G331, C0HJF4,
and C0HJF3, respectively); ShPI-1 (UniProt P31713); AsKC1, AsKC2, and AsKC3 (UniProt KB Q9TWG0,
Q9TWF9, and Q9TWF8, respectively); α-DTX, DTX-I, and DTX K (UniProt KB P00980, P00979, and
P00982, respectively); and BPTI (Uniprot 00974).
3.4. Phylogenetic Analysis
Phylogenetic analysis of the known sea anemone Kunitz-type protease inhibitors was performed
using the neighbor-joining (NJ) method with Poisson correction [75,76] in the MEGA 6 [56].
The bootstrap was performed with 1000 replicates. BPTI was used as an out-group.
3.5. Inhibitory Activity
The trypsin/α-chymotrypsin inhibitory activity of the peptide was tested through the
standard procedure [55] using N-α-benzoyl-D,L-arginine p-nitroanilide hydrochloride (BAPNA)
and ethyl ester of N-benzoyl-L-tyrosine (BTEE) as a substrates, respectively. Determination of the
trypsin/α-chymotrypsin inhibition constants of rHCRG21 was performed according to the method of
Dixon [77] using substrates concentrations of 133 and 65 mM. The concentration of both enzymes in
the reaction mixture was 215 nM. Concentrations of the tested peptide ranged from 0 up to 3.2 mM.
The constants were calculated based on the results of three parallel experiments. Computational error
limits are in the range of 0.1%–0.5%.
3.6. Expression of Voltage-Gated Ion Channels in Xenopus laevis Oocytes
For the expression of rKv1.1, hKv1.3, rKv1.4, rKv1.5, rKv1.6, Shaker IR, hERG, and TRPV1
in Xenopus oocytes, the linearized plasmids were transcribed using the T7 or SP6 mMESSAGE-
mMACHINE transcription kit (Ambion, Austin, TX, USA). The harvesting of stage V–VI oocytes
from anaesthetized female Xenopus laevis frog was previously described [78]. Oocytes were injected
with 50 nL of cRNA at a concentration of 1 ng/nL using a micro-injector (Drummond Scientific,
Broomall, PA, USA). The oocytes were incubated in a solution containing (in mM): NaCl, 96; KCl, 2;
CaCl2, 1.8; MgCl2, 2 and HEPES, 5 (pH 7.4), supplemented with 50 mg/L gentamicin sulfate.
3.7. Electrophysiological Recordings
Two-electrode voltage-clamp recordings were performed at room temperature (18–22 ◦C) using
a Geneclamp 500 amplifier (Molecular Devices, Sunnyvale, CA, USA) controlled by a pClamp data
acquisition system (Axon Instruments, Foster City, CA, USA). Whole cell currents from oocytes were
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recorded 1–4 days after injection. Bath solution composition was ND96 (in mM): NaCl, 96; KCl,
2; CaCl2, 1.8; MgCl2, 2, and HEPES, 5 (pH 7.4). Voltage and current electrodes were filled with
3 M KCl. Resistances of both electrodes were kept between 0.8 and 1.5 MΩ. The elicited currents were
filtered and sampled at, respectively, 1 kHz and 10 kHz (for potassium currents) and at, respectively,
0.2 kHz and 0.5 kHz (for TRPV1 currents), using a four-pole low-pass Bessel filter. Leak subtraction
was performed using a –P/4 protocol. KV1.1–KV1.6 and Shaker currents were evoked by 500 ms
depolarizations to 0 mV followed by a 500 ms pulse to −50 mV, from a holding potential of −90 mV.
Current traces of hERG channels were elicited by applying a +40 mV prepulse for 2 s followed by a
step to −120 mV for 2 s. TRPV1 currents were measured in ND96 solution using a protocol of −90 mV
during 400 s. The recording chamber was perfused at a rate of 2 mL·min−1 with a ND96 solution.
As previously described [79], capsaicin (2 µM) was used as an agonist and capsazepine (10 µM) as an
antagonist of TRPV1. Capsaicin and capsazepine were purchased from Sigma. All data represent at
least 3 independent experiments (n ≥ 3) in which independent experiments represent experiments on
different cells expressing TRPV1 channel and are presented as mean ± standard error.
3.8. Homology Modeling and Docking
Model of HCRG21 peptide was built with methods of homology modeling. A serine protease
inhibitor ShPI-1 of the S. helianthus sea anemone obtained from Protein Data Bank (PDB ID 1SHP)
was used as a template. Structure model of peptide HCRG21 was generated with MOE 15.1001 CCG®
software [80]. Missing loops [61] in Frozen rTRPV1 structures, including a short fragment of 503–507
and the longer extracellular loop 3 of 604–626 of the pore domain have been reconstructed by Loop
Modeler Feature in the program MOE 15.1001, for each loop 10 models as well as models of the
structure of the extracellular and transmembrane domains of the receptor for all the simulated loop
configurations were generated. The models quality was evaluated with the MOE 15.1001 software
and PROCHECK [81] server. Since the receptor structures obtained by cryoelectron microscopy
(3J5Q, 3J5R, 5IRZ, 5IRX, 5IS0) omitted more than 110 N-terminal and 71 C-terminal residues that
form regulatory receptor domain and provide engagement TRPV1 interaction with inhibitory proteins
(calmodulin) [82] and other intracellular partners, our TRPV1 model is adequate for transmembrane,
as well as extracellular domains, including extracellular loops 2 and 3.
Modeling of macromolecular complexes was performed with the molecular docking technique for
each TRPV1 structural model in a capsaicin-bound state with loops refined. Docking procedure
was performed with ClusPro 2.0 server [83,84] and Protein-Protein Docking Feature of MOE
15.1001 software. All computed docking poses were clustered and analyzed. Among top-ranked
docking solutions there were poses corresponding both to the peptide binding site localized at the
transmembrane helix regions and at the cytoplasmic part of the channel, analogous to what has
been reported for APHC1 [32]. However, these solutions were not selected for further analysis due
to a lack of information about how Kunitz peptides insert into the lipid membrane. Concerning the
intracellular part of TRPV1, the lack of new knowledge about regulatory domain structure permits us to
employ receptor structural model [61] as reported earlier [32] for examine putative interaction mode of
HCRG21 with this receptor portion. The most energetically favorable of highly populated and satisfied
the constraints derived from in vitro or in vivo experiments (but non top-ranked) were underwent
MD simulations and analyzed in more details. MD simulations of the HCRG21–TRPV1 complex in a
hydrated POPC lipid bilayer performed in an Amber12:EHT force field [85] were performed under
conditions of constant pressure, 300 K, and pH 7.0 using MOE 15.1001 software [80] for 100 ns. Prior to
MD simulations, whole system was equilibrated to reduce initial bad contacts. Equilibration consisted
in energy minimization of the initial side chains position with fixed backbone atoms, followed by a
minimization with restrained carbon alpha atoms and a short molecular dynamic (100 ps). Computer
simulation and theoretical studies were performed using cluster CCU “Far Eastern computing resource”
FEB RAS (Vladivostok). Analysis of the contact surfaces of theoretical complexes and contribution
of various amino acid residues to the formation of intermolecular interface was performed with
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MOE 15.1001 software [80] and Discovery studio 4.5 Visualizer [86] software. Visualization of the
TRPV1–HCRG21 complex was performed with a Discovery Studio Visualizer BIOVIA® software [86].
4. Conclusions
Kunitz-type peptides attract an increasing attention of investigators because of their important
and intriguing role in many pathophysiological processes. Consequently, these pharmacologically
interesting peptides are intensively being studied as potential drugs for treatment of inflammatory
diseases and pain relief. Electrophysiological data show that the Kunitz-type peptide rHCRG21,
belonging to the H. crispa multigene HCRG peptide subfamily, strongly inhibits the TRPV1 channel.
The HCRG21–TRPV1 molecular docking and MD simulations allow to hypothesize the existence of
two feasible molecular mechanisms of peptide–channel interactions: (i) pore-blocking as a result of
extracellular application (independent of the presence or absence of capsaicin); and (ii) an intercellular
binding with the regulatory channel domain (with three to four subunits) that triggers conformational
changes of the pore helix region structure. Both these possible mechanisms resulted in an obstruction
of the ion flow through TRPV1. At this moment, there is no direct evidence of Kunitz-type peptides
permeating through the membrane and the hereupon following intercellular interaction with TRPV1.
Clearly, more experiments are needed to verify the mechanism by which HCRG21 inhibits the TRPV1
channel. Identification of the key residues of HCRG21, together with site-directed mutagenesis of the
channel, is required. In this work, we report the first venom derived peptide compound that is a full
antagonist of the pain signal transmission through TRPV1. HCRG21 represents a promising tool for
studying TRPV1 channels and, moreover, might be an interesting lead compound for the development
of novel analgesics.
Supplementary Materials: The following are available online at www.mdpi.com/1660-3397/14/12/229/s1,
Table S1: Oligonucleotide primers used and PCR cycling conditions for amplification and hcrg21 gene synthesis,
Table S2: Non-bonded interactions of HCRG21 in complex with intracellular (regulatory) domain of TRPV1
receptor, Table S3: Non-bonded interactions of HCRG21 in complex with extracellular domain of TRPV1 receptor.
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